Health Care

2685 posts

Dream Water Kids Sleep Gummies set for US summer debut

Delivra Health (TSXV:DHB) will launch a new line of kids sleep gummies under its Dream Water brand across the US market this June.

Buzz on the Bullboards: Oil shock, biotech breakthroughs and new tech

Global equities lurched from rally to rout since the U.S.–Israel strikes on Iran ignited a regional war and shutdown of the Strait of Hormuz.

Quit smoking with psychedelics? A new frontier for treatment — and investors

A new Johns Hopkins study found that a single dose of psilocybin, combined with therapy, helped smokers stay cigarette free at six months.

New bladder cancer drug may sharpen radiation’s aim

Theralase Technologies proves that its Rutherrin drug holds the potential to enhance radiation against non-muscle invasive bladder cancer.

FDA grants full approval to Pfizer’s colorectal cancer treatment

The FDA granted full approval to Pfizer’s (NYSE:PFE) BRAFTOVI + cetuximab + fluorouracil based chemotherapy for adults.

Buzz on the Bullboards: Market momentum returns to the TSX?

With markets buzzing on commodity rebounds and fresh economic signals, the TSX is alive with momentum—and...
Organigram

Organigram reports revenue boost in Q1

Organigram (TSX:OGI) reported its Q1 2026 revenue and profit surged, with net revenue up 49 per cent to $63.5M.

Buzz on the Bullboards: Geopolitics are back in the driver’s seat

Geopolitical risk is re‑pricing assets again A renewed wave of geopolitical flashpoints has been rippling through...

MindBio debuts AI speech tool to spot substance abuse

MindBio Therapeutics (CSE:MBIO) develops the world's first AI prediction tool for drug and alcohol intoxication using voice analysis.
The Market Online Video

Developing a neurosciences platform with potential applications across several indications

In this Capital Compass episode, Marvel Biosciences outlines progress on MB-204, its neuroscience platform targeting autism, Rett syndrome, Fragile X, and Alzheimer’s disease ahead…

MediPharm Labs announces CEO transition as David Pidduck steps down

MediPharm Labs (TSX:LABS) CEO David Pidduck will step down on January 23, 2026, and will remain on the Board to support the transition.

An immunotherapy value play advancing the fight against bladder cancer

An in-depth look at BioVaxys Technology (CSE:BIOV), a micro-cap stock combining a promising drug pipeline with irrational investor pessimism.

Theralase and Ferring ink deal for new bladder cancer study

Theralase (TSXV:TLT) and Ferring Pharmaceuticals will evaluate a new combination therapy for high-risk non-muscle invasive bladder cancer.

Buzz on the Bullboards: Energy shockwaves, market movers, and cross-border shifts

From geopolitical shocks in Venezuela to bold plays in fusion and cannabis, this week’s stories share a common thread ....